Interleukin Patents (Class 930/141)
-
Patent number: 5349051Abstract: The present invention relates to modified forms of IL-1.beta. with altered IL-1.beta. activity. The modified IL-1.beta. is the result of mutations which affect amino acids in the beta barrel portion of the IL-1.beta. structural formula. The invention also relates to expression systems that will produce the modified IL-1.beta. polypeptides, and methods of treating susceptible diseases with the modified IL-1.beta. polypeptides.Type: GrantFiled: February 4, 1993Date of Patent: September 20, 1994Assignee: University of MarylandInventor: Balasubramanian Veerapandian
-
Patent number: 5338833Abstract: This invention relates to a Carboxy Terminal IL-6 Mutein with enhanced biological activity. The invention comprises a mutein of IL-6 having increased activity wherein the mutein has an amino acid substitution at, or corresponding to, amino acid location 171 or 175 of IL-6 having the wild-type sequence.Type: GrantFiled: July 23, 1992Date of Patent: August 16, 1994Assignee: The University of North Carolina at Chapel HillInventor: Dana M. Fowlkes
-
Patent number: 5328988Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.Type: GrantFiled: October 6, 1992Date of Patent: July 12, 1994Assignee: Immunex CorporationInventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
-
Patent number: 5319071Abstract: Substantially purified and homogeneous soluble human interleukin-1 receptor (shuIL-1R) proteins, DNA encoding the shuIL-1R proteins and pharmaceutical compositions containing the shuIL-1R proteins are described.Type: GrantFiled: January 14, 1992Date of Patent: June 7, 1994Assignee: Immunex CorporationInventors: Steven K. Dower, Carl J. March, John Sims, David L. Urdal
-
Patent number: 5304637Abstract: Methods are provided for improved production of hIL-3 either in glycosylated form from mammalian and yeast cells or in unglycosylated form from prokaryotes. Recombinantly produced human IL-3 is purified in a series of steps, initially employing hydrophobic interaction, followed by ion exchange chromatography and gel filtration.Type: GrantFiled: March 13, 1990Date of Patent: April 19, 1994Assignee: Gist-brocades N.V.Inventors: Lambertus C. J. Dorssers, Gerard Wagemaker, Yvonne J. Vos, Robert W. Van Leen, Maria L. N. Persoon
-
Patent number: 5290917Abstract: Novel polypeptides having a modified amino acid sequence of human interleukin 1.alpha. polypeptides in which a certain amino acid residue(s) in said amino acid sequence is(are) exchanged for other amino acid residue(s). Said polypeptides having no capacity of induction of production of prostaglandin E.sub.2 while maintaining other biological activities of human interleukin 1 such as activation of lymphocyte and being expected to be useful as a medicament.Type: GrantFiled: April 5, 1991Date of Patent: March 1, 1994Assignee: Dainippon Pharmaceutical Co., Ltd.Inventors: Michiko Yamayoshi, Hitoshi Kawashima, Junichi Yamagishi, Hirotada Kotani, Ryuji Furuta, Toshikazu Fukui
-
Patent number: 5286847Abstract: Disclosed are novel muteins of IL-1 compounds which can be used to regulate excess IL-1 produced in various diseases in humans and animals. The IL-1 muteins can be prepared by site-directed mutagenesis whereby a positively charged residue is replaced with a negatively charged or neutral residue at a designated position in the molecule. The resulting IL-1 muteins have reduced biological activity but retain receptor binding affinity.Type: GrantFiled: May 19, 1992Date of Patent: February 15, 1994Assignees: New England Medical Center Hospitals, Inc., Massachusetts Institute of TechnologyInventors: Lee Gehrke, Philip E. Auron, Lanny Rosenwasser
-
Patent number: 5231012Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs) (now known as interleukin -10), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-.gamma..Type: GrantFiled: July 20, 1992Date of Patent: July 27, 1993Assignee: Schering CorporationInventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
-
Patent number: 5223605Abstract: Isolated and purified Interleukin-4 Binding Protein-.gamma. (IL-4bp.gamma.) and methods for obtaining isolated and purified IL-4bp.gamma..Type: GrantFiled: October 16, 1990Date of Patent: June 29, 1993Assignee: Immunex CorporationInventors: William C. Fanslow, Richard J. Armitage
-
Patent number: 5208218Abstract: The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof and antibodies thereto. The present invention also contemplates a method for inducing the proliferation of helper T cells. The helper T cell growth factor contemplated herein is useful in the stimulation of specific cells in the immune system.Type: GrantFiled: September 19, 1988Date of Patent: May 4, 1993Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Catherine Uyttenhove, Richard J. Simpson
-
Patent number: 5206344Abstract: Muteins of IL-2 in which one of the amino acids of the mature native sequence of IL-2 is replaced by a cysteine residue are prepared and conjugated through the replaced cysteine residue to a polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols, wherein said homopolymers are unsubstituted or substituted at one end with an alkyl group. These muteins are made via host expression of mutant genes encoding the muteins that have been changed from the genes for the parent proteins by site-directed mutagenesis. In addition, other species of IL-2 may be conjugated via the cysteine residue at position 125 of the mature IL-2 protein that is not necessary for the biological activity of the IL-2.Type: GrantFiled: January 11, 1988Date of Patent: April 27, 1993Assignee: Cetus Oncology CorporationInventors: Nandini Katre, Robert F. Halenbeck, Robert J. Goodson, Peter C. McCabe, Michael J. Knauf
-
Patent number: 5180812Abstract: Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal.Type: GrantFiled: December 21, 1989Date of Patent: January 19, 1993Assignee: Immunex CorporationInventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
-
Patent number: 5166322Abstract: Cysteine added variants ("CAVs") of interleukin-3 are provided having one or more cysteine residues substituted for selected naturally occurring amino acid residues, or inserted into the polypeptide sequence, and preferably being further modified by deletion of certain N-terminal amino acids. Such CAVs may be additionally modified by the coupling of sulfhydryl reactive compounds to the introduced cysteine residue(s) without loss of bioactivity to produce selected homogeneously modified IL-3 and improved pharmaceutical compositions containing the same.Type: GrantFiled: April 21, 1989Date of Patent: November 24, 1992Assignee: Genetics InstituteInventors: Gray Shaw, Geertruida Veldman, Joseph L. Wooters
-
Patent number: 5157112Abstract: The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells especially from murine and human sources and further which is capable of augmenting proliferation of IL3- or IL4-responsive cells. Even more particularly, the present inventin relates to the helper T cell growth factor P40, pharmaceutical compositions thereof, antibodies thereto and recombinant DNA clones thereof. The present invention also contemplates a method for inducing the proliferation of helper T cells as well as IL3- and Il4-responsive cells. The helper T cells growth factor contemplated herein is useful in the stimulation of specific cells in the immune system, either alone or in combination with IL3 or IL4.Type: GrantFiled: September 15, 1989Date of Patent: October 20, 1992Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Catherine Uyttenhove, Richard J. Simpson
-
Patent number: 5128450Abstract: The present invention provides a pharmaceutical compositions comprising as active ingredients certain truncated purified human IL-3(Pro.sup.8 Asp.sup.15 Asp.sup.70) analog proteins expressed by transformed yeast of the species Saccharomyces cerevisiae, which when administered to a primate do not result in detectable urticaria.Type: GrantFiled: June 30, 1989Date of Patent: July 7, 1992Inventors: David L. Urdal, Helmut M. Sassenfeld
-
Patent number: 5102872Abstract: Shipping fever, and other stress-related diseases in livestock, are treated by administration of a microencapsulated composition comprising IL-2 conjugated with a polyoxyethylene polymer, and mixed with a release-modulating amount of humen serum albumin. The microcapsules are administered parenterally, and release an effective amount of conjugated IL-2 continuously over a period of 14-30 days. These microcapsules are also effective in the treatment of cancer in mammals.Type: GrantFiled: August 12, 1988Date of Patent: April 7, 1992Assignee: Cetus CorporationInventors: Maninder Singh, Jack H. Nunberg, Thomas R. Tice, Michael E. Hudson, Richard M. Gilley, Terrance A. Taforo